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Abstract 
Peptidomimetics based on hydrazino derivatives of α-amino acids represent an important class of peptidic fol-
damers with promising biological activities, like protease inhibition and antimicrobial activity. However, the lack of 
straightforward method for the synthesis of optically pure hydrazino acids and efficient incorporation of hydrazino 
building blocks into peptide sequence hamper wider exploitation of hydrazino peptidomimetics. Here we described 
the utility of Nα-benzyl protected and unprotected hydrazino derivatives of natural α-amino acids in synthesis of 
peptidomimetics. While incorporation of Nα-benzyl-hydrazino acids into peptide chain and deprotection of benzyl 
moiety proceeded with difficulties, unprotected hydrazino acids allowed fast and simple construction of hybrid 
peptidomimetics.
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Background
Proteins and their conjugates are key players in funda-
mental molecular functions that define life as we know. 
Despite the relatively small number of constitutive ele-
ments, 20 canonical amino acids, the structural and 
functional diversity of proteins stems from their abil-
ity to adopt discrete three-dimensional folded struc-
tures. Understanding the interplay between amino 
acid sequence, protein structure and a biological func-
tion remains one of the most challenging tasks (Horne 
2011). Traditionally, peptides and proteins were placed 
far away from the focus of medicinal chemistry owing to 
the poor enzymatic stability and cell permeability. How-
ever, peptide-based therapeutics became highly impor-
tant over the last few decades. The increased number of 
identified therapeutic targets and substantially upgraded 
delivery systems made peptide market growing almost 
twice as fast as the overall pharmaceutical market (Kas-
par and Reichert 2013). Attempts to mimic folding prop-
erties of proteins led to the development of “foldamers”, 
non-natural oligomers able to adopt stable three-dimen-
sional structure (Gellman 1998; Hill et al. 2001; Bautista 
et al. 2007).
Research efforts in construction of foldamers with 
predictable folding properties and desirable biological 
responses are directed mainly toward two classes of oli-
gomers: arylamide and peptidic foldamers. Arylamide 
foldamers are composed of either aryl amino acids or 
combinations of aryldiamines and aryldiacids, where 
intramolecular hydrogen bonding and the intrinsic rigid-
ity of arylamide units dictate conformation (Li et al. 2008; 
Zhu et  al. 2011; Kudo et  al. 2013; Guichard and Huc 
2011). Peptidic foldamers are formally derived from the 
natural α-peptide sequence via backbone homologation 
(Horne 2011; Martinek and Fülöp 2012; Bandyopad-
hyay et  al. 2014; Hegedüs et  al. 2013; Avan et  al. 2014). 
Intervention into peptide backbone by incorporation of 
non-natural amino acids or replacement of peptide bond 
with isosteres has a major implication on peptidomi-
metic properties. Medium-sized bridged heterocycles 
(La-Venia et  al. 2014), sulfono-γ-amino acids (Wu et al. 
2015), cyclopentane-based γ-amino acid (Giuliano et al. 
2013), 2-aminobenzenesulfonic acid (Kale et  al. 2013), 
N-amino-imidazolin-2-ones (Proulx and Lubell 2012) are 
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some examples of effective secondary structure inducers 
upon incorporation into peptide backbone. Replacement 
of α-carbon or backbone extension leads to oligomers 
with well-established folding properties: azapeptides, 
azadepsipeptides, β- and γ-peptides, aminoxypeptides, 
and hydrazinopeptides (Avan et  al. 2014). Hydrazino 
derivatives of α-amino acids can be derived from 
β-amino acids through replacement of β carbon atom 
with nitrogen. Repulsion of lone electron pairs placed at 
neighbouring nitrogen atoms, yields the observed pro-
nounced rigidity of peptidomimetics with incorporated 
hydrazino derivatives (Cheguillaume et  al. 2001). Also, 
intramolecular hydrogen bonding pattern in such pep-
tidomimetics promotes formation of unique secondary 
structure, known as hydrazino-turn (Acherar et al. 2013; 
Salaün et al. 2006; Cheguillaume et al. 2001). Hydrazino-
based peptidomimetics show promising biological activi-
ties, like protease inhibition (Bordessa et al. 2013; Aubin 
et  al. 2005) and antimicrobial activity (Laurencin et  al. 
2012a, b). It is therefore important to have a method for 
fast and easy construction of such templates.
The most utilized hydrazino building block described 
in the literature is N-substituted hydrazino acetic acid; 
an achiral monomer readily prepared from substi-
tuted hydrazines and bromoacetic esters (Bonnet et  al. 
2003). Synthesis of optically pure hydrazino derivatives 
is a more challenging task. Generally, there are three 
approaches (Avan et  al. 2014; Maraud and Vanderesse 
2004): N-amination of N-benzyl derivatives of natural 
amino acids with N-Boc oxaziridines; Shestakov rear-
rangement, the conversion of urea derivatives to hydra-
zines using hypochlorite; and the conversion of α-amino 
acids to α-bromo acids followed by the nucleophilic sub-
stitution reaction of hydrazine with inversion of configu-
ration. There are many drawbacks associated with each 
procedure. Electrophilic amination with N-Boc oxaziri-
dines ensures optical integrity of the obtained hydrazino 
acids, however procedure suffers from the lack of repro-
ducibility. Nucleophilic substitution of α-bromo acids 
with hydrazine is a rather simple and economic two-step 
procedure, but incomplete conversions were observed 
in some cases (Panda et  al. 2013). Also, the adjacent 
nitrogen atoms, Nα and Nβ are both reactive; therefore 
regioselectivity during the synthesis of hydrazino-based 
peptidomimetics arose as a central issue when using 
derivatives with unprotected Nα atom (Maraud and Van-
deresse 2004).
We present here our findings on synthesis of di- and 
tripeptides with embedded hydrazino acids derived from 
natural amino acids. Both, Nα-benzyl hydrazino acids 
(Nα-Bn hAaa) and unprotected hydrazino acids (hAaa) 
(Scheme 1) were used to test their utility in synthesis of 
hybrid peptidomimetics.
Experimental section
Reactions were monitored by TLC on Silica Gel 60 F254 
plates (Merck) using detection with ninhydrin. The 
melting points were determined on a Tottoli (Büchi) 
apparatus and were uncorrected. Column chromatogra-
phy was performed on Silica Gel (Merck, 0.040–0.063). 
Chiral TLC was performed on chiral Silica Gel 60 F254 
plates (Aldrich). NMR spectra were recorded on 600 
and 300  MHz Bruker spectrometers, operating at 150. 
92 or 75.47 MHz for 13C and 600.13 or 300.13 MHz for 
1H nuclei. TMS was used as an internal standard. HRMS 
analysis was performed on MALDI-TOF/TOF mass 
spectrometer operating in reflectron mode. Mass spectra 
were acquired by accumulating three spectra after 400 
laser shots per spectrum. Calibrant and analyte spectra 
were obtained in positive ion mode. Calibration type 
was internal with calibrants produced by matrix ioniza-
tion (monomeric, dimeric and trimeric CHCA), with 
azithromycin and angiotensin II dissolved in a-cyano-
4-hydroxycinnamic acid matrix in the mass range m/z 
190.0499–749.5157 or 1046.5417. Accurately measured 
spectra were internally calibrated and elemental analy-
sis was performed on Data Explorer v. 4.9 Software with 
mass accuracy better than 5 ppm. Samples were prepared 
by mixing 1 lμL of analyte methanol solution with 5 μL 
of saturated (10 mg/mL) solution of a-cyano 4-hydroxy-
cinnamic acid (a-CHCA) and internal calibrants (0.1 mg/
mL) dissolved in 50 % acetonitrile/0.1 % TFA. Microwave 
assisted reactions were performed on CEM Discovery 
System with infrared temperature control. The reaction 
mixtures were placed in a flask equipped with a magnetic 
stir bar and subjected to microwave irradiation.
Nα-benzyl-Nβ-Boc amino acids 1 were prepared 
according to procedure described by Lelais and Seebach 
(2003). N-benzyl-α-amino acid (1 equiv.) was dissolved in 
dry MeOH and (CH3)4NOH (1 equiv.) was added at 0 °C. 
After 30 min solvent was evaporated and the residue dis-
solved in dry CH2Cl2. The solution was cooled to −78 °C 
and N-Boc-3-trichloromethyloxaziridine (1.3 equiv., 
prepared according to Vidal et  al. (1998)) dissolved in 
CH2Cl2 was added dropwise. Reaction was stirred at 
room temperature overnight. Solution was washed three 
Scheme 1 Structure of Nα-benzyl hydrazino acid (Nα-Bn hAaa) and 
hydrazino acid (hAaa)
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times with water, collected water layers were acidified 
with KHSO4 to pH 3 and product extracted with CH2Cl2. 
Solvent was evaporated and the product (yellow oil, 40 %) 
used without further purification. α-Hydrazino acids 
were prepared according the procedure described by 
Panda et  al. (2013), with slight modifications. d-Amino 
acid was dissolved in 2.5  M H2SO4 (1.3  mL/mmol) and 
KBr (3.5 equiv.) was added. The solution was cooled 
down to 0 °C and then solution of NaNO2 (1.3 equiv.) was 
added dropwise. After 1 h at 0  °C, the reaction mixture 
was stirred at room temperature overnight. α-Bromo 
acid was extracted with EtOAc, washed with NaHCO3 
and dried over MgSO4. After evaporation, product was 
obtained as yellow oil (85  % yield.). Obtained α-bromo 
acid was dissolved in EtOH (2 mL) and added dropwise to 
solution of hydrazine hydrate (3 equiv.) in EtOH (1 mL). 
The reaction mixture was irradiated under MW at 70 °C 
and 50 W for 1 h. A white suspension was obtained. Sol-
vent was evaporated, and product recrystallized from 
EtOH/ether (40  % yield). Optical purity of prepared 
hydrazino acids has been checked by the chiral thin-layer 
chromatography and confirmed complete conversion.
General procedure for the synthesis of dipeptides 2
Dipeptides were prepared by acid mediated removal 
of the Boc group from the corresponding N-terminally 
protected dipeptides (TFA-water 9:1, v/v; 30  min.; r.t.; 
quant.). N-terminally protected dipeptides were obtained 
by the following procedure: Boc-Aaa-OH (Aaa  =  Leu, 
Val, Ala) (1  mmol) and HOSu (1.5  mmol) were dis-
solved in dry DMF (3  mL) and solution cooled down 
to 0  °C. DCC (1.5  mmol) dissolved in dry DMF (2  mL) 
was added dropwise. After 30  min reaction was stirred 
at room temperature and the consumption of starting 
dipeptide followed by TLC. The precipitate was filtered, 
and the filtrate added dropwise to the solution of H-Phe-
R (R=OH, OEt or NH2) (1 mmol) and KHCO3 (2 mmol) 
in water (5  mL). Reaction mixture was stirred at room 
temperature overnight. Solvent was evaporated and the 
residue purified by the flash column chromatography. 
Mobile phase used for the chromatography was also used 
for the determination of Rf value and is given for each 
compound.
Boc‑Leu‑Phe‑OH
Colourless oil (0.68  g, 82  %); Rf 0.40 (petrol ether-
EtOAc-AcOH 7:5:0.5). 1H NMR (300  MHz, [D6]DMSO, 
25 °C): δ = 12.6 (br s, 1H, OH), 7.88 (d, 3JNH,H = 7.9 Hz, 
1H, NH Phe), 7.31–7.10 (m, 5H, δ, ε, ζ Phe), 6.83 (d, 
3JNH,H = 8.6 Hz, 1H, NH Leu), 4.49–4.38 (m, 1H, α Phe), 
4.00–3.88 (m, 1H, α Leu), 3.05; 2.90 (dd, 3JH,H = 5.1 Hz, 
3JH,H = 8.6 Hz, 2JH,H = 13.9 Hz, 2H, β, β′ Phe), 1.55–1.46 
(m, 3H, β, β′, γ Leu), 1.36 (s, 9H, CH3 Boc), 0.83; 0.80 (d, 
3JH,H = 6.6 Hz, 6H, δ, δ′ Leu). 13C NMR (300 MHz, [D6]
DMSO, 25  °C): δ  =  172.8 (CO Phe), 172.3 (CO Leu), 
155.1 (CO Boc), 137.3 (γ Phe), 129.0 (δ Phe), 128.0 (ε 
Phe), 126.4 (ζ Phe), 78.0 (C Boc), 53.1 (α Phe), 52.8 (α 
Leu), 41.0 (β Leu), 36.7 (β Phe), 28.1 (CH3 Boc), 24.1 (γ 
Leu), 22.8; 21.6 (δ, δ′ Leu).
Boc‑Val‑Phe‑OH
Colourless oil (0.45 g, 54 %); Rf 0.38 (petrol ether-EtOAc-
AcOH 7:5:0.5). 1H NMR (300  MHz, [D6]DMSO, 25  °C): 
δ = 8.04 (d, 3JNH,H = 7.8 Hz, 1H, NH Phe), 7.29–7.10 (m, 
5 H, δ, ε, ζ Phe), 6.57 (d, 3JNH,H =  8.2  Hz, 1H, NH Val), 
4.42 (m, 1H, α Phe), 3.76 (m, 1H, α Val), 3.05; 2.88 (dd, 
3JH,H = 5.2 Hz, 3JH,H = 8.5 Hz, 2JH,H = 13.8 Hz, 2H, β, β′ 
Phe), 1.84 (m, 1H, β Val), 1.37 (s, 9H, CH3 Boc), 0.74; 0.77 
(d, 3JH,H = 6.6 Hz, 6H, γ, γ′ Val). 13C NMR (300 MHz, [D6]
DMSO, 25 °C): δ = 172.8 (CO Phe), 171.3 (CO Val), 155.2 
(CO Boc), 137.0 (γ Phe), 129.1 (δ Phe), 128,1 (ε Phe), 126.4 
(ζ Phe), 78.1 (C Boc), 59.7 (α Val), 53.2 (α Phe), 36.8 (β 
Phe), 30.5 (β Val), 28.2 (CH3 Boc), 19.1; 18.1 (γ, γ′ Val).
Boc‑Ala‑Phe‑OH
Colourless oil (1.78 g, 36 %); Rf 0.30 (petrol ether-EtOAc-
AcOH 7:5:0.5). 1H NMR (300 MHz, [D6]DMSO, 25  °C): 
δ = 7.83 (d, 3JNH,H = 7.7 Hz, 1H, NH Phe), 7.30–7.15 (m, 
5H, δ, ε. ζ Phe), 6.81 (d, 3JNH,H =  6.5  Hz, 1H, NH Ala), 
4.40 (m, 1H, α Phe), 3.95 (m, 1H, α Ala), 3.04; 2.91 (dd, 
3JH,H = 5.1 Hz, 3JH,H = 8.4 Hz, 2JH,H = 13.9 Hz, 2H, β, β′ 
Phe), 1.36 (s, 9H, CH3 Boc), 1.12 (d, 3JH,H = 7.0 Hz, 3H, β 
Ala). 13C NMR (300 MHz, [D6]DMSO, 25 °C): δ = 172.6 
(CO Phe), 172.5 (CO Ala), 154.8 (CO Boc), 137.3 (γ Phe), 
129.1 (δ Phe), 128.0 (ε Phe), 126.3 (ζ Phe), 77.5 (C Boc), 
53.1 (α Phe), 49.6 (α Ala), 18.1 (β Ala), 36.7 (β Phe), 28.1 
(CH3 Boc).
Boc‑Leu‑Phe‑NH2
White powder (0.31 g, 83 %); m.p. 140 °C; Rf 0.35 petrol 
ether:EtOAc:AcOH (10:5:0.5). 1H NMR (300  MHz, [D6]
DMSO, 25  °C): δ  =  7.70 (d, 3JNH,H  =  7.8  Hz, 1H, NH 
Phe), 7.31–7.14 (m, 5H, δ, ε, ξ Phe), 7.36; 7.12 (br s, 2H, 
CONH2), 6.96 (d, 3JNH,H = 8.5 Hz, 1H, NH Leu), 4.45 (m, 
1H, α Phe), 3.84 (m, 1H, α Leu), 3.00–2.82 (m, 2H, β, β′ 
Phe), 1.79–1.55 (m, 2H, β, β′ Leu), 1.55–1.44 (m, 1H, γ 
Leu), 1.37 (s, 9H, CH3 Boc), 0.84; 0.80 (d, 3JH,H = 6.6 Hz, 
6H δ, δ′ Leu). 13C NMR (300  MHz, [D6]DMSO, 25  °C): 
δ = 172.5 (CO Leu), 155.7 (CO Boc), 137.2 (γ Phe), 129.1 
(δ Phe), 128.0 (ε Phe), 126.3 (ζ Phe), 78.6 (C Boc), 53.9 (α 
Phe), 53.6 (α Leu), 48.0 (β Leu), 38.1 (β Phe), 28.1 (CH3 
Boc), 24.6 (γ Leu), 23.3; 22.1 (δ, δ′ Leu).
Boc‑Val‑Phe‑NH2
White powder (0.33  g, 90  %); m.p. 148  °C; Rf 0.33 (pet-
rol ether:EtOAc:AcOH 10:5:0.5). 1H NMR (300  MHz, 
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[D6]DMSO, 25  °C): δ  =  7.75 (d, 3JNH,H  =  7.7  Hz, 1H, 
NH Phe), 7.30–7.14 (m, 5H, δ, ε, ξ Phe), 7.32; 7.02 (br 
s, 2H, CONH2), 6.64 (d, 3JNH,H =  8.0  Hz, 1H, NH Val), 
4.60–4.35 (m, 1H, α Phe), 3.75–3.60 (m, 1H, α Val), 2.96; 
2.83 (dd, 3JH,H = 5.0 Hz, 3JH,H = 8.5 Hz, 2JH,H = 13.8 Hz, 
2H, β, β′ Phe), 1.75–1.68 (m, 1H, β Val), 1.37 (s, 9H, CH3 
Boc), 0.72; 0.68 (d, 3JH,H = 6.6 Hz, 6H, γ, γ′ Val). 13C NMR 
(300 MHz, [D6]DMSO, 25 °C): δ = 173.2 (CO Val), 156.3 
(CO Boc), 137.0 (γ Phe), 129.2 (δ Phe), 128.0 (ε Phe), 
126.2 (ζ Phe), 78.6 (C Boc), 60.2 (α Val), 54.0 (α Phe), 37.6 
(β Phe), 30.7 (β Val), 28.6 (CH3 Boc), 19.1; 18.1 (γ, γ′ Val).
Boc‑Ala‑Phe‑NH2
White powder (0.24 g, 72 %); m.p. 157 °C; Rf 0.14 (petrol 
ether:EtOAc:AcOH 10:5:0.5). 1H NMR (300  MHz, [D6]
DMSO, 25 °C): δ = 7.65 (d, 3JNH,H = 7.8 Hz, 1H, NH Phe), 
7.25–7.15 (m, 5H, δ, ε. ζ Phe), 7.00 (d, 3JNH,H =  6.4  Hz, 
1H, NH Ala), 7.45; 7.10 (br s, 2H, CONH2), 4.43 (m, 1H, 
α Phe), 3.87 (m, 1H, α Ala), 3.04–2.91 (m, 2H, β, β′ Phe), 
1.36 (s, 9H, CH3 Boc), 1.07 (d, 3JH,H = 6.8 Hz, 3H, β Ala). 
13C NMR (300 MHz, [D6]DMSO, 25 °C): δ = 172.6 (CO 
Phe), 172.3 (CO Ala), 156.6 (CO Boc), 137.1 (γ Phe), 
129.0 (δ Phe), 128.1 (ε Phe), 126.3 (ζ Phe), 78.1 (C Boc), 
53.2 (α Phe), 47.3 (α Ala), 36.7 (β Phe), 28.1 (CH3 Boc), 
18.0 (β Ala).
General procedure for the synthesis of tripeptides 3a 
and 3b
Nα-benzyl-Nβ-Boc amino acid 1 (0.5  mmol) was dis-
solved in dry DMF, NMM (0.5 mmol), BOP (0.55 mmol) 
and HOBt (0.55  mmol) were added. After 30  min solu-
tion of dipeptide 2 (0.5 mmol) and NMM (0.5 mmol) in 
dry DMF (1 mL) was added. Reaction was stirred at room 
temperature overnight. Solvent was evaporated and the 
residue purified by the flash column chromatography. 
Mobile phase used for the chromatography was also used 
for the determination of Rf value and is given for each 
compound.
Nα‑benzyl‑Nβ‑Boc‑Leu‑Leu‑Phe‑OH (3a)
Yellow oil (56  mg, 19  %); Rf 0.66 (petrol 
ether:EtOAc:AcOH 5:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25 °C): δ = 8.29 (d, 3JNH,H = 7.9 Hz, 1H, NH Phe), 
7.88 (d, 3JNH,H =  8.8  Hz, 1H, NH), 7.78 (br s, 1H, NH), 
7.65–7.55 (m, 5H, Bn), 7.26–7.16 (m, 5H δ, ε, ξ Phe), 4.53 
(m, 1H, α Phe), 4.43 (m, 1H, α Leu), 4.34 (m, 1H, α hLeu), 
3.79 (s, 2H, CH2 Bn), 3.00–2.89 (m, 2H β, β′ Phe), 1.53 
(m, 3H, β, γ Leu), 1.42–1.34 (m, 3H, β, γ hLeu), 1.33–1.25 
(m, 9H CH3 Boc), 0.84–0.74 (m, 12H, δ, δ′, Leu, hLeu). 
13C NMR (151 MHz, [D6]DMSO, 25 °C): δ = 172.9, 171.6, 
170.4 (CO Phe, Leu, hLeu), 154.9 (CO Boc), 137.6 (C 
Bn), 137.4 (γ Phe), 133.1, 132.4, 131.4 (CH Bn), 129.1, 
128.1, 127.0 (δ, ε, ζ Phe), 78.2 (α hLeu), 60.1 (α Phe), 53.2 
(CH2 Bn), 50.7 (α Leu), 37.0 (β Leu), 36.8 (β Phe), 36.6 (β 
hLeu), 28.0 (CH3 Boc), 24.2 (γ hLeu), 23.8 (γ Leu), 23.0 (δ 
hLeu), 22.8 (δ Leu), 21.7 (δ′ hLeu), 21.4 (δ′ Leu). HRMS 
(MALDI-TOF/TOF): calcd. for C33H48N4O6 [M +  Na]+ 
619.3466; found 619.3446.
Nα‑benzyl‑Nβ‑Boc‑Val‑Val‑Phe‑OH (3b)
Yellow oil (66  mg, 12  %); Rf 0.50 (petrol 
ether:EtOAc:AcOH 10:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25  °C): δ  =  7.62–7.56 (m, 5H, Bn), 7.45–7.24 
(m, 5H, δ, ε, ξ Phe), 4.43 (m, 1H, α Phe), 4.33–4.12 (m, 
2H, α Val, hVal), 3.84–3.66 (m, 2H, CH2 Bn), 3.05–2.95 
(m, 2H, β Phe), 2.02–1.85 (m, 2H, β Val, hVal), 1.29–1.17 
(m, 9H, CH3 Boc), 0.93–0.70 (m, 12H, γ, γ′ Val, hVal). 13C 
NMR (151  MHz, [D6]DMSO, 25  °C): δ  =  172.7, 170.6, 
163.8 (CO Phe, Val, hVal), 154.3 (CO Boc), 137.5 (C Bn), 
137.4 (γ Phe), 133.1, 132.4, 131.4 (CH, Bn), 128.7, 128.0, 
127.8 (δ, ε, ζ Phe), 78.6 (C Boc), 78.1 (α hVal), 60.8 (α Phe), 
57.3 (CH2 Bn), 53.1 (α Val), 36.6 (β Phe), 34.7 (β hVal), 
30.4 (β Val), 28.0 (CH3 Boc), 19.3, 18.8 (γ, γ′ hVal), 18.3, 
17.9 (γ, γ′ Val). HRMS (MALDI-TOF/TOF): calcd. for 
C31H44N4O6 [M + K]+ 607.2892; found 607.291.
General Procedure for the synthesis of tripeptides 3c–3g
Nα-benzyl-Nβ-Boc amino acid 1 (0.5  mmol) and dipep-
tide 2 (0.5  mmol) were dissolved in dry DMF; NMM 
(1 mmol), BOP (0.55 mmol) and HOBt (0.55 mmol) were 
added. Reaction was stirred at room temperature over-
night. Solvent was evaporated and the residue purified by 
the flash column chromatography. Mobile phase used for 
the chromatography was also used for the determination 
of Rf value and is given for each compound.
Nα‑benzyl‑Nβ‑Boc‑Leu‑Leu‑Phe‑OEt (3c)
Yellow oil (32  mg, 10  %); Rf 0.75 (petrol 
ether:EtOAc:AcOH 10:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25 °C): δ = 8.57 (d, 3JNH,H = 7.4 Hz, 1H, NH), 8.32 
(d, 3JNH,H = 7.2 Hz, 1H, NH), 7.79 (d, 3JNH,H = 7.5 Hz, 1H, 
NH), 7.42–7.08 (m, 10H, Bn, δ, ε, ξ Phe), 4.50–4.33 (m, 
3H, α Phe, CH2 OEt), 4.07–3.95 (m, 2H, CH2 Bn), 3.80 
(m, 1H, α Leu), 3.48–3.32 (m, 1H, α hLeu), 3.07–2.90 (m, 
2H, β, β′ Phe), 1.66–1.40 (m, 6H, β, β′, γ Leu, hLeu), 1.40–
1.17 (m, 9H, CH3 Boc), 1.12–1.06 (m, 3H, CH3 OEt), 
0.93–0.75 (m, 12H, δ, δ′ Leu, hLeu). 13C NMR (151 MHz, 
[D6]DMSO, 25 °C): δ = 171.8, 171.2, 170.6 (CO Phe, Leu, 
hLeu), 156.0 (CO Boc), 137.5 (C Bn), 137.1 (γ Phe), 129.0, 
128.8, 128.1 (CH Bn), 127.8, 127.0, 126.5 (δ, ε, ζ Phe), 78.2 
(α hLeu), 76.3 (C Boc), 60.4 (CH2 OEt), 60.1 (CH2 Bn), 
53.7 (α Leu), 53.5 (α Phe), 51.4 (β Phe), 40.1 (β hLeu), 
36.4 (β Leu), 28.0 (CH3 Boc), 24.2 (γ hLeu), 24.0 (γ Leu), 
22.9; 22.8 δ, δ′ hLeu), 21.5; 21.2 (δ, δ′ Leu), 13.8 (CH3 
OEt). HRMS (MALDI-TOF/TOF): calcd. for C35H52N4O6 
[M + Na]+ 647.3779; found 647.3766.
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Nα‑benzyl‑Nβ‑Boc‑Val‑Val‑Phe‑OEt (3d)
Yellow oil (82  mg, 27  %); Rf 0.71 (petrol 
ether:EtOAc:AcOH 10:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25 °C): δ = 8.65 (d, 3JNH,H = 7.2 Hz, 1H, NH), 8.27 
(d, 3JNH,H =  7.3  Hz, 1H, NH), 7.65 (d, 3JNH,H =  7.4  Hz, 
1H, NH),7.66–7.53 (m, 5H, Bn), 7.31–7.16 (m, 5H, δ, ε, 
ξ Phe), 4.45 (m, 2H, CH2 OEt), 4.31–4.24 (m, 1H, α Phe), 
4.23–4.17 (m, 1H, α Val), 4.17–4.10 (m, 1H, α hVal), 4.01 
(m, 2H, CH2 Bn), 3.01–2.94 (m, 2H, β, β′ Phe), 1.93 (m, 
1H, β hVal), 1.72 (m, 1H, β Val), 1.65–1.25 (m, 9H, CH3 
Boc), 1.16–1.00 (m, 6H, γ, γ′ Val), 0.94–0.86 (m, 3H, CH3 
OEt), 0.85–0.75 (m, 6H, γ, γ′ hVal). 13C NMR (151 MHz, 
[D6]DMSO, 25 °C): δ = 171.2, 170.7, 160.7 (CO Phe, Val, 
hVal), 156.6 (CO Boc), 133.1 (Bn), 132.4 (γ Phe), 132.1, 
131.5, 131.4 (CH Bn), 129.0, 128.7, 128.1 (δ, ε, ζ Phe), 
60.4 (α hVal), 57.2 (α Val), 55.5 (α Phe), 53.5 (CH2 OEt), 
47.5 (β Bn), 36.5 (β Phe), 33.3 (β hVal), 30.7 (β Val), 28.0 
(CH3 Boc), 25.3, 24.4 (γ, γ′ hVal), 19.1, 17.9 (γ, γ′ Val), 
13.9 (CH3 OEt). HRMS (MALDI-TOF/TOF): calcd. for 
C33H48N4O6 [M + Na]+ 619.3466; found 619.3478.
Nα‑benzyl‑Nβ‑Boc‑Leu‑Leu‑Phe‑NH2 (3e)
Yellow oil (212  mg, 71  %); Rf 0.48 (petrol 
ether:EtOAc:AcOH 7:5:0.5). 1H NMR (600  MHz, 
CD3OD, 25  °C): δ =  7.42–7.04 (m, 12H, δ, ε, ξ Phe, Bn, 
CONH2), 4.65; 4.58 (m, 1H, α Phe), 4.40; 4.19 (m, 1H, 
α Leu), 3.46; 3.32 (m, 1H, α hLeu), 3.14–2.77 (m, 2H, β, 
β′ Phe), 1.87–1.45 (m, 6H, β, β′, γ Leu, hLeu), 1.29 (br s, 
9H, Boc), 0.94–0.80 (m, 12H, δ, δ′ Leu, hLeu). 13C NMR 
(151 MHz, CD3OD, 25  °C): δ = 175.8, 174.4, 172.6 (CO 
Phe, Leu, hLeu), 158.7 (CO Boc), 137.9 (γ Phe), 137.0, 
129.6, 129.5, 129.4 (Bn), 129.1 (ε Phe), 128.5 (δ Phe), 127.8 
(ε Phe), 80.8 (C Boc), 61.8 (CH2 Bn), 55.6, 55.5 (α Phe), 
53.8, 53.0 (α Leu), 49.7 (α hLeu), 41.4, 41.1 (β Leu), 40.2, 
40.1 (β Phe), 38.9, 38.3 (β hLeu), 28.6 (CH3 Boc), 25.8, 
25.4 (γ Leu, hLeu), 23.4, 23.0, 22.5, 21. 8 (δ, δ′ Leu, hLeu). 
HRMS (MALDI-TOF/TOF): calcd. for C33H49N5O5 
[M + Na]+ 618.3625; found 618.3618.
Nα‑benzyl‑Nβ‑Boc‑Val‑Val‑Phe‑NH2 (3f)
Yellow oil (195  mg, 69  %); Rf 0.46 (petrol 
ether:EtOAc:AcOH 5:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25  °C): δ =  8.11, 7.96, 7.75 (br d, 3H, NH Phe, 
Val, hVal), 7.42-7.19 (m, 10H, Bn, Phe), 7.16 (br s, 2H, 
NH2), 4.49 (m, 1H, α Phe), 4.22 (m, 1H, α Val), 3.76 (m, 
2H, CH2 Bn,), 3.08-2.91 (m, 2H, β, β′ Phe), 2.81 (m, 1H, α 
hVal), 1.96 (m, 1H, β Val), 1.86 (m, 1H, β hVal), 1.32-1.13 
(br s, 9H CH3 Boc), 1.07-0.65 (m, 12H, γ, γ′ Val, hVal). 
13C NMR (151 MHz, [D6]DMSO, 25 °C): δ = 172.6 (CO 
Phe), 170.3, 170.1 (CO Val, hVal), 163.7 (CO Boc), 137.7 
(γ Phe),), 137.6 (C Bn), 132.0, 131.5, 128.7 (CH Bn), 128.0, 
127.8, 126.9, (δ, ε, ζ Phe), 78.1 (C Boc), 60.3 (CH2 Bn), 
57.6 (α Val), 53.5 (α Phe), 37.6 (β Phe), 30.2 (β Val), 28.0 (β 
hVal), 19.3 (CH3 Boc), 18.9, 18.3 (γ, γ′ Val, hVal). HRMS 
(MALDI-TOF/TOF): calcd. for C31H45N5O5 [M +  Na]+ 
590.3313; found 590.3334.
Nα‑benzyl‑Nβ‑Boc‑Ala‑Ala‑Phe‑NH2 (3g)
Yellow oil: (176  mg, 69  %); Rf 0.31 
(EtOAc:EtOH:AcOH:H2O 70:10:2:2). 1H NMR 
(600 MHz, [D6]DMSO, 25 °C): δ = 7.40–7.35 (br s, 3H. 
NH Ala, hAla, Phe), 7.30–7.18 (m, 10H, Bn, Phe), 7.15 
(s, 2H, NH2), 4.41 (m, 1H, α Phe), 4.22 (m, 1H, α Ala), 
3.82 (s, 2H, CH2 Bn), 3.57 (m, 1H, α hAla), 3.04–2.81 
(m, 2 H, β, β′ Phe), 1.40 (m, 6H, β Ala, hAla), 1.22 (s, 
9H, CH3 Boc). 13C NMR (151 MHz, [D6]DMSO, 25 °C): 
δ = 172.6 (CO Phe), 171.9 (CO, Ala), 171.6 (CO, hAla), 
137.8 (Bn), 136.9 (γ Phe), 129.2, 128.2, 127.9 (CH Bn), 
127.8, 127.0, 126.8, (δ, ε, ζ Phe), 78.5 (C Boc), 62.2 (α 
hAla), 53.6 (α Phe), 48.0 (α Ala), 37.4 (β Phe), 28.2 (CH3 
Boc), 21.0 (β Ala), 17.8 (β hAla). HRMS (MALDI-TOF/
TOF): calcd. for C27H37N5O5 [M  +  Na]+ 534.2686; 
found 534.2699.
General procedure for the synthesis 
of Nα‑benzyl‑Nβ‑Boc‑Aaa‑Gly‑OH 4a and 4b
Nα-benzyl-Nβ-Boc-Aaa-OH (Aaa = Leu, Val) (0.45 mmol) 
and HOSu (0.5 mmol) were dissolved in 3 mL dry DMF 
and solution cooled down to 0 °C. DCC (0.5 mmol) dis-
solved in 2  mL dry DMF was added dropwise. After 
30  min reaction was stirred at room temperature and 
the consumption of starting dipeptide followed by TLC. 
The precipitate was filtered, and the filtrate added drop-
wise to the solution of glycine (0.45 mmol) and KHCO3 
(0.45  mmol) in 5  mL of water. Reaction mixture was 
stirred at room temperature overnight. Solvent was 
evaporated and the residue purified by the flash column 
chromatography. Mobile phase used for the chromatog-
raphy was also used for the determination of Rf value and 
is given for each compound.
Nα‑benzyl‑Nβ‑Boc‑Leu‑Gly‑OH (4a)
Yellow oil: (117  mg, 52  %); Rf 0.57 (EtOAc:petrol 
ether:AcOH 10:5:0.5). 1H NMR (600 MHz, CDCl3, 25 °C): 
δ = 7.57–7.03 (m, 5H, Bn), 5.52 (s, 2H, CH2 Bn), 4.12 (br 
s, 2H, α Gly), 3.46–3.36 (m, 1H, α Leu), 1.95–1.88 (m, 
2H, β Leu), 1.59 (m, 1H, γ Leu), 1.54–1.21 (m, 9H, CH3 
Boc), 1.15–0.75 (m, 6H, δ, δ′ Leu). 13C NMR (151 MHz, 
CDCl3, 25 °C): δ = 175.8 (CO Gly), 163.1 (CO Leu), 157.9 
(CO Boc), 129.7, 128.9, 128.0 (CH Bn), 64.0 (α Leu), 61.3 
(CH2 Bn), 49.7 (α Gly), 36.9 (β Leu), 28.5 (CH3 Boc), 
25.2 (γ Leu), 21.1, 21.0 (δ, δ′ Leu). HRMS (MALDI-TOF/
TOF): calcd. for C20H31N3O5 [M + Na]+ 416.2156; found 
416.2166.
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Nα‑benzyl‑Nβ‑Boc‑Val‑Gly‑OH (4b)
Yellow oil (82  mg, 46  %); Rf 0.70 (petrol 
ether:EtOAc:AcOH 7:5:0.5). 1H NMR (600  MHz, [D6]
DMSO, 25  °C): δ =  8.51–7.09 (m, 5H, Bn), 5.09 (s, 2H, 
CH2 Bn), 3.96–3.68 (m, 1H, α Val), 3.60–2.96 (m, 2H α 
Gly), 1.39 (m, 1H, β Val), 1.32–1.18 (m, 9H, CH3 Boc), 
1.08–0.99 (m, 6H, γ, γ′ Val). 13C NMR (151  MHz, [D6]
DMSO, 25 °C): δ = 173.5 (CO Gly), 171.0 (CO Val), 156.6 
(CO Boc), 128.9, 127.8, 126.8 (CH Bn), 78.6 (C Boc), 
76.8 (α Val), 65.5 (CH2 Bn), 47.5 (α Gly), 28.0 (CH3 Boc), 
25.0 (β Val), 19.3, 18.2 (γ, γ′ Val). HRMS (MALDI-TOF/
TOF): calcd. for C19H29N3O5 [M + Na]+ 402.1999; found 
402.2005.
Synthesis of Nα‑benzyl‑Nβ‑Boc‑Leu‑OMe (5a)
Nα-benzyl-Nβ-Boc-Leu-OH (100 mg, 0.3 mmol) was dis-
solved in dry DMF (10 mL), KHCO3 (60 mg, 0.59 mmol) 
was added and then CH3I (30 μL, 0.48 mmol) dropwise. 
Reaction mixture was stirred at room temperature over-
night. Water was added to the reaction and product 
extracted with EtOAc. Yellow oil: (102 mg, 95 %); Rf 0.64 
(petrol ether:EtOAc:AcOH 15:5:0.5). ESI–MS: m/z 373 
[M + Na]+.
Synthesis of Nα‑benzyl‑Nβ‑Boc‑Ala‑OMe (5b)
Nα-benzyl-Nβ-Boc-Ala-OH (100 mg, 0.3 mmol) was dis-
solved in dry DMF (10 mL), KHCO3 (60 mg, 0.59 mmol) 
was added and then CH3I (30 μL, 0.48 mmol) dropwise. 
Reaction mixture was stirred at room temperature over-
night. Water was added to the reaction and product 
extracted with EtOAc. Yellow oil (109 mg, 100 %); Rf 0.83 
(petrol ether:EtOAc:AcOH 7:5:0.5). 1H NMR (600 MHz, 
CD2Cl2, 25 °C): δ = 7.32 (br d, 1H, NH hAla), 7.40–7.24 
(m, 5H, Bn), 4.02–3.91 (m, 2H, CH2 Bn), 3.71 (s, 3H, 
OCH3), 3.63 (m, 1H, α hAla), 1.36 (d, 3JH,H  =  7.3  Hz, 
3H, β hAla), 1.34 (s, 9H, CH3 Boc). 13C NMR (151 MHz, 
CD2Cl2, 25 °C): δ = 164.6 (CO Ala), 137.8 (C Bn), 132.5, 
128.7, 127.9 (CH Bn), 79.8 (C Boc), 76.5 (α hAla), 61.8 
(CH2 Bn), 52.1 (OCH3), 28.5 (CH3 Boc), 16.6 (β hAla). 
ESI–MS: m/z 331 [M + Na]+, m/z 209 [M-Boc]+.
Synthesis of Nα‑benzyl‑hLeu‑OMe (6a)
Crude product 5a was dissolved in TFA-water 9:1, v/v) 
and the reaction was stirred at room temperature 60 min. 
Solvent was evaporated and the residue dried in vacuum.
Synthesis of Nα‑benzyl‑Nβ‑Boc‑Leu‑Nα‑benzyl‑Leu‑OMe (7)
Nα-benzyl-Nβ-Boc-Leu-OH (100 mg; 0.3 mmol) was dis-
solved in dry DMF, NMM (55 μL, 0.50 mmol) and HATU 
(125 mg, 0.33 mmol) were added. After 15 min solution 
of Nα-benzyl-hydrazino leucine (100 mg; 0.3 mmol) and 
NMM (55 μL, 0.50 mmol) in 1 mL dry DMF was added. 
Reaction was stirred at room temperature overnight. 
Solvent was evaporated and the residue purified by flash 
column chromatography in petrol ether:EtOAc:AcOH 
10:5:0.5. Yellow oil: (80  mg, 47  %); Rf 0.53 (petrol 
ether:EtOAc:AcOH 15:5:0.5). ESI–MS: [M  +  H]+ m/z 
569.3; [M + Na]+ m/z 591.3. 1H NMR (600 MHz, CD2Cl2, 
25 °C): δ = 7.49–7.14 (m, 10H, Bn), 6.86 (br s, 1H, NH), 
5.83 (d, 3JNH,H = 10.5 Hz, 1H, NH), 3.99–3.94 (m, 2H, α 
hLeu), 3.78–3.62 (m, 7 H, CH2, Bn, CH3 O–CH3), 1.63–
1.56 (m, 4H, β, β′ hLeu), 1.38–1.31 (m, 9H, CH3 Boc), 
0.99–0.87 (m, 14H, γ, δ, δ′ hLeu). 13C NMR (151  MHz, 
CD2Cl2, 25 °C): δ = 172.8, 172.7 (CO hLeu), 137.1, 137.0 
(C Bn), 128.9, 128.1, 127.7, 127.6, 127.0, 126.0 (CH Bn), 
80.9 (C Boc), 66.0 (CH2 Bn), 66.0, 62.2 (α hLeu), 60.6 
(CH2 Bn), 50.9 (OCH3), 38.7, 38.5 (β hLeu), 27.4 (CH3 
Boc), 24.2, 23.7 (γ Leu), 22.1, 20.9 (δ, δ′, hLeu). HRMS 
(MALDI-TOF/TOF): calcd. for C32H48N46O5 [M +  K]+ 
607.3256; found 607.3256.
Synthesis of Nβ‑Boc‑Leu‑OMe (8a)
Nα-benzyl-Nβ-Boc-Leu-OMe (240  mg, 0.71  mmol) was 
dissolved dry MeOH (45  mL), acetic acid (3  mL) and 
10 % Pd/C (90 mg) were added. Reaction was performed 
under 15 atm H2 at room temperature for 3 days. Catalyst 
was filtered off, solvent evaporated and the residue puri-
fied by flash chromatography. Yellow oil: (88 mg; 48 %); 
Rf =  0.58 (petrol ether:EtOAc:AcOH 15:5:0.5). ESI–MS: 
[M-Boc]+ m/z 161.2; [M + H]+ m/z 261.2.
Synthesis of Nβ‑Boc‑Phe‑OMe (8b)
Nα-benzyl-Nβ-Boc-Phe-OMe (100  mg, 0.26  mmol) was 
dissolved in dry MeOH (40 mL), acetic acid (3 mL) and 
10 % Pd/C (26 mg) were added Reaction was performed 
under 15 atm H2 at room temperature for 3 days. Cata-
lyst was filtered off, solvent evaporated and the residue 
purified by the flash column chromatography. Yellow 
oil: (57 mg; 74 %); Rf =  0.44 (petrol ether:EtOAc:AcOH 
15:5:0.5). 1H NMR (600 MHz, CD2Cl2, 25 °C): δ = 7.33–
7.22 (m, 6H, NH, δ, ε, ζ Phe), 6.16 (br. s, 1H, NH Phe), 
3.93 (m, 1H, α hPhe), 3.69 (s, 3H, O–CH3), 3.05, 2.91 
(m, 2H, β, β′ hPhe), 1.40 (s, 9H, CH3 Boc). 13C NMR 
(151  MHz, CD2Cl2, 25  °C): δ =  172.4 (CO hPhe), 155.6 
(CO Boc), 136.5 (γ hPhe), 128.7, 127.0, 126.3 (δ, ε, ζ 
hPhe), 79.8 (C Boc), 63.6 (α hPhe), 51.3 (OCH3), 36.4 (β 
hPhe), 27.4 (CH3 Boc). ESI–MS: [M-Boc]+ m/z 195.1; 
[M + H]+ m/z 295.1; [M + Na]+ m/z 317.1; [2 M + H]+ 
m/z 589.3; [2 M + Na]+ m/z 611.3
Synthesis of Boc‑Lys(Boc)‑hLeu‑OH (9)
Boc-Lys(Boc)-OH (236  mg, 0.68  mmol) and HOSu 
(117 mg, 1.02 mmol) were dissolved in dry DMF (3 mL) 
and solution cooled down to 0  °C. DCC (210  mg, 
1.02  mmol) dissolved in dry DMF (2  mL) was added 
dropwise. After 30  min reaction was stirred at room 
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temperature and the consumption of starting dipep-
tide followed by TLC. The precipitate was filtered, 
and the filtrate added dropwise to the solution of hLeu 
(100 mg, 0.68 mmol) and KHCO3 (136 mg, 1.36 mmol) 
in water (5  mL). Reaction mixture was stirred at room 
temperature overnight. Solvent was evaporated and 
the residue purified by the flash column chromatog-
raphy (mobile phase: EtOAc:AcOH 70:2). Yellow oil: 
(156  mg, 48  %); Rf 0.38 (EtOAc:AcOH 70:2). ESI–MS: 
[M +  H]+ m/z 475, [M-Boc]+ m/z 375, [M-2Boc]+ m/z 
275. 1H NMR (600  MHz, CDCl3, 25  °C): δ =  4.83–4.62 
(m, 1H, α Lys), 3.83–3.60 (m, 1H, α hLeu), 3.16–3.07 (m, 
2H, ε Lys), 1.90–1.50 (m, 8H, β, δ Lys, β hLeu, γhLeu,), 
1.42 (m, 18H, CH3 Boc), 1.33 (m, 2H, γ Lys), 0.99, 0.96 
(d, 3JH,H = 6.6 Hz, 6H, δ, δ′ hLeu). 13C NMR (151 MHz, 
CDCl3, 25  °C): δ =  175.4 (CO hLeu), 52.9 (α Lys), 47.7 
(α hLeu), 40.3 (β hLeu), 39.6 (ε Lys), 32.3 (β Lys), 29.8 (δ 
Lys), 28.4 (CH3 Boc), 25.1 (γ hLeu), 23.1 (γ Lys), 22.7, 
22.1 (δ, δ′ hLeu). HRMS (MALDI-TOF/TOF): calcd. for 
C22H42N4O7 [M + Na]+ 497.2945; found 497.2937.
Synthesis of Boc‑Lys(Boc)‑hLeu‑Leu‑OH (10)
Compound 9 (100  mg, 0.21  mmol) and HOSu (37  mg, 
0.32 mmol) were dissolved in dry DMF (3 mL) and solu-
tion cooled down to 0 °C. DCC (65 mg, 0.32 mmol) dis-
solved in dry DMF (2  mL) was added dropwise. After 
30 min reaction was stirred at room temperature and the 
consumption of starting dipeptide followed by TLC. The 
precipitate was filtered, and the filtrate added dropwise to 
the solution of leucine (28 mg, 0.21 mmol) and KHCO3 
(42  mg, 0.42  mmol) in water (5  mL). Reaction mixture 
was stirred at room temperature overnight. Solvent was 
evaporated and the residue purified by the flash column 
chromatography (mobile phase: EtOAc:AcOH 70:2). Yel-
low oil: (61 mg, 49 %); Rf 0.73 (EtOAc:AcOH 70:2). ESI–
MS: [M +  H]+ m/z 588.7, [2  M +  H]+ m/z 1176.1. 1H 
NMR (600 MHz, CDCl3, 25 °C): δ = 5.27 (m, 1H, α Leu), 
3.88–3.59 (m, 1H, α Lys), 3.46 (m, 1H, α hLeu), 3.12 (m, 
2H, ε Lys), 1.75–1.68 (m, 2H, β Lys), 1.67–1.58 (m, 2H, 
δ Lys), 1.58–1.51 (m, 2H, β Leu, hLeu), 1.51–1.41 (m, 
18H, CH3 Boc), 1.38–1.32 (m, 2H, γ Lys), 1.22–0.82 (m, 
12H, δ, δ′ Leu, hLeu). 13C NMR (151 MHz, CDCl3, 25 °C): 
δ =  176.2 (CO Leu), 175.3 (CO hLeu), 171.7 (CO Lys), 
157.2 (CO Boc), 76.5 (C Boc), 63.9 (α hLeu), 61.5 (α Lys), 
55.5 (α Leu), 41.1 (ε Lys), 40.4 (β Leu), 33.8 (β hLeu), 31.5 
(β Lys), 29.7 (δ Lys), 28.4, 28.3 (CH3 Boc), 25.6 (γ hLeu), 
24.9 (γ Leu), 23.5 (γ Lys), 23.1, 23.0 (δ, δ′ hLeu), 22.7, 
22.5 (δ, δ′ Leu). HRMS (MALDI-TOF/TOF): calcd. for 
C28H53N5O8 [M + K]+ 626.3524; found 626.3542.
Synthesis of Boc‑Lys(Boc)‑hLeu‑hLeu‑OH (11)
Compound 9 (100 mg, 0.21 mmol) was dissolved in dry 
DMF; NMM (23 μL, 0.21  mmol) and HATU (88  mg, 
0.23  mmol) were added. After 15  min solution of hLeu 
(31 mg, 0.21 mmol) and NMM (23 μL, 0.21 mmol) in dry 
DMF (1  mL) was added. Reaction was stirred at room 
temperature overnight. Solvent was evaporated and the 
residue purified by the flash column chromatography 
(mobile phase: EtOAc:AcOH 70:2). Yellow oil: (68  mg, 
53  %); Rf 0.35 (EtOAc:AcOH 70:2). ESI–MS: [M +  H]+ 
m/z 603.6, [M-Boc]+ m/z 503.6. 1H NMR (600  MHz, 
MeOD, 25  °C): δ =  3.96 (m, 1H, α Lys), 3.49 (m, 2H, α 
hLeu), 3.06 (m, 2H, ε Lys), 1.89 (m, 2H, β Lys), 1.77–1.73 
(m, 2H, δ Lys), 1.66–1.55 (m, 6H, β, β′, γ hLeu), 1.47 (m, 
18H, CH3 Boc), 1.41–1.37 (m, 2H, γ Lys,), 1.02–0.98 (m, 
12H, δ, δ′, hLeu). 13C NMR (151  MHz, CDCl3, 25  °C): 
δ = 178.1 (CO hLeu), 172.1 (CO hLeu), 170.9 (CO Lys), 
157.2 (CO Boc), 82.1 (C Boc), 79.1 (C Boc), 66.3 (α hLeu), 
63.9 (α Lys), 57.8 (α hLeu), 41.3 (β hLeu), 40.1 (ε Lys), 
38.6 (α hLeu), 33.8 (β Lys), 29.6 (δ Lys), 28.4, 28.3 (CH3 
Boc), 25.6 (γ hLeu), 24.8 (γ hLeu), 22.8 (γ Lys), 22.1, 22.0, 
21.9 (δ,δ′ hLeu). HRMS (MALDI-TOF/TOF): calcd. for 
C28H54N6O8 [M + Na]+ 625.3895; found 625.3914.
Results and discussion
Hydrazino derivatives of leucine, valine and alanine were 
prepared by two procedures: (1) electrophilic amination 
of the corresponding N-benzyl-l-amino acid with N-Boc 
oxaziridine (Lelais and Seebach 2003), and (2) nucleo-
philic substitution of d-amino acid-derived α-bromo acid 
with hydrazine hydrate (Panda et  al. 2013). While first 
procedure yielded Nα-benzyl-Nβ-Boc amino acid deriva-
tives in ≈40 % yield, second approach gave rise to unpro-
tected hydrazino acids also in 40 % yield.
The utility of Nα-benzyl-Nβ-Boc amino acid derivatives 
as building blocks in synthesis of peptidomimetics was 
tested by coupling with Aaa-Phe dipeptides (Aaa = Leu, 
Val, Ala), carrying acid, ester or amide group at the 
C-terminus (Scheme 2). Guy et al. (1998) performed vari-
ous activation of Nα-benzyl-Nβ-Boc-Ala-OH and found 
PyBOP to be the most effective. Similarly, Lelais and 
Seebach (2003) observed that HATU activation is more 
effective that EDC/HOBt. We have tested activation of 
Nα-benzyl-Nβ-Boc-l-leucine 1a by mixed anhydride, 
DCC/HOSu, BOP and HATU, and only BOP and HATU 
activation gave products. However, free tripeptide acids 
were obtained in low yields (19 % for 3a and 12 % for 3b, 
Table 1). We then repeated couplings with ethyl ester of 
dipeptides 2 and gained corresponding tripeptide esters, 
again in low yields, (10 % for 3c and 27 % for 3d; Table 1). 
Switching to dipeptide amides turned out to be crucial 
for improving couplings; amides 3e–g were obtained in 
≈70  % yields (Table  1). Since the same carboxyl com-
ponent, and the same coupling conditions were used in 
all examples, the reason for the observed difference was 
sought in conformation preferences of dipeptides 2.
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Vijayadas et  al. (2013) undertook crystallographic and 
NMR spectroscopic studies on a simple two-residue 
reversed-turn mimetics with C-terminal ester and amide 
groups and revealed that amides tend to form intramo-
lecular hydrogen bond and stabilize folded conformation 
with higher propensity then the corresponding esters. 
However, these studies were performed in non-polar 
aprotic CDCl3, where intramolecular hydrogen bonds 
are expected. Close inspection of NMR spectra corre-
sponding to dipepetide esters vs amides, revealed two set 
of signals in both 1H and 13C NMR spectra of dipeptide 
amides 2e–g, while only one set of resonances is pre-
sent in spectra of dipeptide esters 2c and 2d. Respective 
example is given at Fig. 1 for the 1H NMR spectra of ester 
2c and amide 2e. Spectra were recorded in [D7]DMF to 
correspond closely to the conditions present during the 
peptide coupling. Two set of signals exhibit NH, Hα and 
Hβ, β′ protons of the Phe residue (Fig.  1), but also Leu 
side-chain protons (Additional file 1: Figure S1). Two set 
of signals, present in relative ratio 75:25, were assigned 
to trans and cis isomers of the Leu-Phe amide bond. 1H 
NMR spectrum of 2e was also acquired at elevated tem-
peratures (40, 60 and 80 °C; Additional file 1: Figure S2) 
and ratio of two sets of signals remains the same.
It is known that the free energy barrier for the trans–cis 
isomerization of peptidyl-prolyl amide bonds (Aaa-Pro) 
is in a range 60–100 kJ/mol, leading to the 5–40 % of cis 
isomer present in an unordered peptide chains (Jabs et al. 
1999). Nonprolyl peptide bonds were found experimen-
tally to contain about 0.5 % of cis isomer in dipeptides and 
about 0.15 % in longer peptides. Among them, aromatic 
amino acids are frequently found as residues flanking cis 
peptide bonds (Wawra and Fisher 2006). NMR study of 
Scherer et al. (1998) revealed that peptide bonds adjacent 
to the aromatic amino acid generate cis isomer popula-
tion in a range 0.1–1 %, depending on a peptide length. 
Since NMR spectra of free dipeptide acids and dipep-
tide esters confirmed presence of a single conformer 
and those of dipeptide amides revealed presence of two 
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3c R1 = R2 = -CH2CH(CH3)2 R3 = OEt (10 %)
3d R1 = R2 = -CH(CH3)2 R3 = OEt (27 %)
3e R1 = R2 = -CH2CH(CH3)2 R3 = NH2 (71 %)
3f R1 = R2 = -CH(CH3)2 R3 = NH2 (69 %)
3g R1 = R2 = -CH3 R3 = NH2 (69 %)
4a R1 = -CH2CH(CH3)2 (51 %)
4b R1 = -CH(CH3)2 (46 %)
BOP/HOBt, NMM
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Scheme 2 Synthesis of peptides based on Nα-benzyl hydrazino derivatives
Table 1 Preparation of hydrazino tripeptides 3a–g
a Isolated yields
Product R1 R2 R3 Yielda
3a –CH2CH(CH3)2 –CH2CH(CH3)2 OH 19
3b –CH(CH3)2 –CH(CH3)2 OH 12
3c –CH2CH(CH3)2 –CH2CH(CH3)2 OEt 10
3d –CH(CH3)2 –CH(CH3)2  OEt 27
3e –CH2CH(CH3)2 –CH2CH(CH3)2 NH2 71
3f –CH(CH3)2 –CH(CH3)2 NH2 69
3g –CH3 –CH3 NH2 69
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conformers, it can be assumed that C-terminal amide 
group stabilizes cis conformation of the Aaa-Phe pep-
tide bond. This stabilization is significant; having in mind 
that ratio of two isomers corresponds to those expected 
for the peptidyl–prolyl amide bonds (Wawra and Fisher 
2006). It can be assumed that in polar solvents, like DMF, 
nucleophilic attack by the amino group on the activated 
carboxyl group of 1, is more efficient in cis population 
of amides 2e–f, since tripeptide amides are obtained in 
considerably higher yields than the corresponding esters 
of acids where only trans population is present. However, 
steric effects cannot be neglected. As a matter of fact, 
coupling of 1a and 1b with unprotected glycine gave cor-
responding hydrazino dipeptides 4a and 4b in fair yields 
(51 and 46 %, respectively; Scheme 2). Further elongation 
of peptide chain through coupling with Nα-Bn-hLeu-OH 
gave only mixture of inseparable product, therefore, we 
decided to use C-terminal protected derivative, Nα-Bn-
hLeu-OMe and couple it with 1a. Activation with HATU 
was performed and dipeptide 7 was isolated in 47 % yield.
Next, we examined deprotection of Nα-benzyl-
hydrazino units. It is known that catalytic hydrogenolysis 
of N-benzyl group proceeds slow and is often incomplete, 
or even unsuccessful. Interestingly, there are examples 
where Boc-deprotection or/and saponification of deben-
zylated Boc-protected peptide esters were ineffective 
(Lelais and Seebach 2003). We tested benzyl group 
removal on Nα-benzyl-Nβ-Boc phenylalanine and leucine 
methyl esters and applied two procedures. Reaction with 
ammonium-formate in acidic media performed in reflux 
of methanol gave, after 3 days 32 % of debenzylated prod-
uct, while 74  % of the desired product was obtained by 
catalytic hydrogenolysis. Reaction was performed under 
15 atm H2 for 3 days at room temperature (Scheme 3).
Obtained results pointed to numerous obstacles asso-
ciated with the usage of Nα-benzyl hydrazino acids, 
starting from their incorporation into peptide chain to 
deprotection of the benzyl group. There are examples 
where coupling of Nα-protected hydrazino derivatives 
to the activated amino acids, during solution and solid-
phase synthesis was less effective (Bouillon et al. 2007a, 
b). Here we encountered problems with coupling to the 
activated Nα-protected hydrazino acids and found that 
the conformational preferences of the nucleophile highly 
influence the outcome of the coupling reaction.
Therefore, we turned out attention to hydrazino acids 
(hAaa) obtained by the second approach. Panda et  al. 
(2013) have recently shown that benzotriazolidines of 
the Nβ-Cbz hydrazino acids undergo acylation with chi-
ral N-, O-, S, and C-nucleophiles. We further explored 
the utility of hydrazino derivatives of α-amino acids 
through series of couplings presented at Scheme 4. First 
Fig. 1 Parts of the 1H NMR spectra of dipeptide ester 2c and dipeptide amide 2e ([D7]DMF) showing single or two sets of signals, respectively
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we tested coupling of Boc-Lys(Boc)-OH and C-terminally 
unprotected hydrazino derivative of l-leucine (hLeu) 
and obtained product 9 in 48 % yield. Encouraged by this 
result, we performed two additional reactions to elongate 
peptide chain. Coupling of hydrazino dipeptide 9 with 
Leu through DCC/HOSu activation gave hydrazino trip-
eptide 10 in 49 % yield, while coupling with hLeu in the 
presence of HATU gave hydrazino tripeptide 11 in 53 % 
yield. It is know that activation of unprotected hydrazino 
acids may encounter side reactions leading to undesired 
diketopiperazines or various oligomers (Bently and Mor-
ley 1966; Guy et al. 1998; Maraud and Vanderesse 2004). 
Guy et al. (1998) found that activation with DCC/HOSu 
can be successful only if activated ester is formed in situ. 
Also, acylation with unprotected hydrazino acids took 
place regioselectively on the Nβ when both amino acid 
partners bear bulky side chains. Similarly as Panda et al. 
(2013), and Acherer et al. (2013) we did not observe indi-
cation of oligomerization products under the applied 
reaction condition. The presence of bulky side chains and 
relatively efficient activation of the carboxyl component 
most probably contributed to this result. Acherar et  al. 
(2013) have previously prepared mixed [α/α-hydrazino]
tetra- and octamer using C-terminally protected hAla-
OMe. Here we showed that acylation reactions pro-
ceed smoothly with fully unprotected nucleophiles, 
thus allowing simple elongation of peptide chain and 
construction of hybrid hydrazino peptidomimetics with 
either alternating (like in 10) or sequential (like in 11) 
distribution of hydrazino acids along the sequence.
Although hydrazino peptides can be considered as 
extension of the β-peptide concept, conformational 
preferences of hydrazino peptides are considerably less 
described. Acherar et al. (2013) studied mixed foldamers, 
and found various conformations of hybrid oligomers 
composed of α-amino and α-hydrazino acids. We assume 
that such conformational flexibility could be important 
for the adaptability of hydrazino peptides in interaction 
with biomolecules, particularly nucleic acids. It is known 
that minor groove of the DNA is target of many non-
covalent binding compounds, where beside electrostatic 
and van der Waals interactions, hydrogen bonding pat-
tern is essential for a recognition process (Lauria et  al. 
2007). Therefore, we plan to expand here described con-
cept of peptidomimetics with alternating and sequential 
distribution of hydrazino units on series of derivatives, to 
probe the binding to nucleic acids.
Conclusions
We have prepared Nα-benzyl hydrazino acids (Nα-Bn 
hAaa) and unprotected hydrazino acids (hAaa) and tested 
their utility in synthesis of di- and tripeptides. We found 
that the coupling to the activated Nα-protected hydrazino 
acids depends on steric and conformational character-
istics of nucleophile, while deprotection of benzyl moi-
ety requires harsh reaction conditions. Contrary to that, 
unprotected hydrazino acids allowed fast and simple 
construction of hybrid peptidomimetics with alternating 
and sequential distribution of hydrazino units.
Additional files
Additional file 1: Figure S1. 1H NMR spectra of compounds 2c and 2e 
([D7]DMF)2c.
Additional file 2: Figure S2. Temperature-dependent 1H NMR spectra 
of 2e ([D7]DMF).
Scheme 3 Deprotection of Nα-benzyl group in Nα-benzyl-Nβ-Boc 
amino acids
Scheme 4 Synthesis of peptides based on hydrazino derivative of 
l-leucine
Page 11 of 12Suć and Jerić  SpringerPlus  (2015) 4:507 
Abbreviations
BOP: (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hex-
afluorophosphate; DCC: N,N′-dicyclohexylcarbodiimide; EDC: 
3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine; HATU: 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate; HOBt: 1-hydroxybenzotriazole; HOSu: N-hydroxysuccin-
imide; NMM: N-methylmorpholine; PyBOP: (benzotriazol-1-yloxy)tripyrrolidi-
nophosphonium hexafluorophosphate; TFA: trifluoroacetic acid; TLC: thin-layer 
chromatography; TMS: tetramethylsilane.
Authors’ contributions
JS carried out all experimental work. IJ designed the study and drafted the 
manuscript. Both authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Ruđer Bošković Institute.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no conflict of interest.
Received: 6 July 2015   Accepted: 28 August 2015
References
Acherar S, Salaün A, Le Grel P, Le Grel B, Jamart-Grégoire B (2013) Conforma-
tional behavior of 1:1 [α/α-hydrazino]mer, 1:1 [α/aza-β3-amino]mer and 
1:1 [aza-β3-amino/α]mer series: three series of foldamers. Eur J Org Chem 
5603–5613. doi:10.1002/ejoc.201300567
Aubin S, Martin B, Delcros JG, Arlot-Bonnemains Y, Baudy-Floc’h M (2005) Retro 
hydrazino-azapeptoids as peptidomimetics of proteosome inhibitors. J 
Med Chem 48:330–334. doi:10.1021/jm049455f
Avan I, Hall CD, Katritzky AR (2014) Peptidomimetics via modifications 
of amino acids and peptide bonds. Chem Soc Rev 43:3575–3594. 
doi:10.1039/c3cs60384a
Bandyopadhyay A, Malik A, Kumar MG, Gopi HN (2014) Exploring β-hydroxy 
γ-amino acids (statines) in the design of hybrid peptide foldamers. Org 
Lett 16:294–297. doi:10.1021/ol403290h
Bautista AD, Craig CJ, Harker EA, Schepartz A (2007) Sophistication of foldamer 
form and function in vitro and in vivo. Curr Opin Chem Biol 11:685–692. 
doi:10.1016/j.cbpa.2007.09.009
Bently PH, Morley JS (1966) Polypeptides. Part 1 l. A hydrazino-peptide ana-
logue of norophthalmic acid amide. J Chem Soc C 60–64. doi:10.1039/
J39660000060
Bonnet D, Grandjean C, Rousselot-Pailley P, Joly P, Bourel-Bonnet L, Santraine V, 
Gras-Masse H, Melnyk O (2003) Solid-phase functionalization of peptides 
by an α-hydrazinoacetyl group. J Org Chem 68:7033–7040. doi:10.1021/
jo0343432
Bordessa A, Keita M, Maréchal X, Formicola L, Lagarde N, Rodrigoa J, Bernadat 
G, Bauvais C, Soulier JL, Dufau L, Milcent T, Crousse B, Reboud-Ravauxb M, 
Ongeri S (2013) α- and β-hydrazino acid-based pseudopeptides inhibit 
the chymotrypsin-like activity of the eukaryotic 20S proteasome. Eur J 
Med Chem 70:505–524. doi:10.1016/j.ejmech.2013.09.059
Bouillon I, Brosse N, Vanderesse R, Jamart-Gregoire B (2007a) Synthesis of Nα-Z, 
Nβ-Fmoc or Boc protected α-hydrazinoacids and study of the coupling 
reaction in solution of Nα-Z-α-hydrazinoesters. Tetrahedron 63:2223–
2234. doi:10.1016/j.tet.2006.12.085
Bouillon I, Vanderesse R, Brosse N, Fabre O, Jamart-Gregoire B (2007b) Solid-phase 
synthesis of hydrazinopeptides in Boc and Fmoc strategies monitored by 
HR-MAS NMR. Tetrahedron 63:9635–9641. doi:10.1016/j.tet.2007.07.038
Cheguillaume A, Salaün A, Sinbandhit S, Potel M, Gall P, Baudy-Floch M, Le Grel 
P (2001) Solution synthesis and characterization of aza-β3-peptides (Nα-
substituted hydrazino acetic acid oligomers). J Org Chem 66:4923–4929. 
doi:10.1021/jo001500d
Gellman SH (1998) Foldamers: a manifesto. Acc Chem Res 31:173–180. 
doi:10.1021/ar960298r
Giuliano MW, Maynard SJ, Almeida AM, Reidenbach AG, Guo L, Ulrich EC, Guzei 
IA, Gellman SH (2013) Evaluation of a cyclopentane-based γ-amino acid 
for the ability to promote α/γ-peptide secondary structure. J Org Chem 
78:12351–12361. doi:10.1021/jo401501g
Guichard G, Huc I (2011) Synthetic foldamers. Chem Commun 47:5933–5941. 
doi:10.1039/C1CC11137J
Guy L, Vidal J, Collet A (1998) Design and synthesis of hydrazinopeptides and 
their evaluation as human leukocyte elastase inhibitors. J Med Chem 
41:4833–4843. doi:10.1021/jm980419o
Hegedüs Z, Wéber E, Kriston-Pál É, Makra I, Czibula Á, Monostori É, Martinek TA 
(2013) Foldameric α/β-peptide analogs of the β-sheet-forming antian-
giogenic anginex: structure and bioactivity. J Am Chem Soc 135:16578–
16584. doi:10.1021/ja408054f
Hill DJ, Mio MJ, Prince RB, Hughes TS, Moore JS (2001) A field guide to foldam-
ers. Chem Rev 101:3893–4011. doi:10.1021/cr990120t
Horne WS (2011) Peptide and peptoid foldamers in medicinal chemistry. 
Expert Opin Drug Discov 6:1247–1262. doi:10.1517/17460441.2011.632
002
Jabs A, Weiss MS, Hilgenfeld R (1999) Non-proline cis peptides bonds in pro-
teins. J Biol Chem 286:291–304. doi:10.1006/jmbi.1998.2459
Kale SS, Priya G, Kotmale AS, Gawade RL, Puranik VG, Rajamohanan PR, 
Sanjayan GJ (2013) Orthanilic acid-promoted reverse turn formation in 
peptides. Chem Commun 49:2222–2224. doi:10.1039/c3cc40522b
Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics 
development. Drug Discov Today 18:807–817
Kudo M, Maurizot V, Kauffmann B, Tanatani A, Huc I (2013) Folding of a linear 
array of α-amino acids within a helical aromatic oligoamide frame. J Am 
Chem Soc 135:9628–9631. doi:10.1021/ja404656z
Laurencin M, Amor M, Fleury Y, Baudy-Floc’h M (2012a) De Novo cyclic 
pseudopeptides containing aza-β3-amino acids exhibiting antimicrobial 
activities. J Med Chem 55:10885–10895. doi:10.1021/jm3009037
Laurencin M, Legrand B, Duval E, Henry J, Baudy-Floc’h M, Zatylny-Gaudin C, 
Bondon A (2012b) From a marine neuropeptide to antimicrobial pseu-
dopeptides containing aza-β3-amino acids: structure and activity. J Med 
Chem 55:2025–2034. doi:10.1021/jm2011595
Lauria A, Montalbano A, Barraja P, Dattolo G, Almerico AM (2007) 
DNA minor groove binders: an overview on molecular mod-
eling and QSAR approaches. Curr Med Chem 14:2136–2160. 
doi:10.2174/092986707781389673
La-Venia A, Ventosa-Andrés P, Hradilová L, Krchňák V (2014) From amino acids 
to nature-inspired molecular scaffolds: incorporation of medium-sized 
bridged heterocycles into a peptide backbone. J Org Chem 79:10378–
10389. doi:10.1021/jo501983j
Lelais G, Seebach D (2003) Synthesis, CD spectra, and enzymatic stability of 
β2-oligoazapeptides prepared from (S)-2-hydrazino carboxylic acids car-
rying the side chains of Val, Ala, and Leu. Helv Chim Acta 86:4152–4168. 
doi:10.1002/hlca.200390342
Li ZT, Hou JL, Li C (2008) Peptide mimics by linear arylamides: a structural 
and functional diversity test. Acc Chem Res 41:1343–1353. doi:10.1021/
ar700219m
Maraud M, Vanderesse R (2004) (N-Aminoamide) Peptides. In: Felix AF, 
Moroder L, Goodman M, Toniolo C (eds) Methods in organic chemistry, 
synthesis of peptides and peptidomimetics. Georg Thieme, Stuttgart, pp 
434–443
Martinek TA, Fülöp F (2012) Peptidic foldamers: ramping up diversity. Chem 
Soc Rev 41:687–702. doi:10.1039/c1cs15097a
Panda SS, El-Nachef C, Bajaj K, Katritzky AR (2013) Syntheses of hydrazino 
peptides and conjugates. Eur J Org Chem 19:4156–4162. doi:10.1002/
ejoc.201201731
Proulx C, Lubell WD (2012) N-Amino-imidazolin-2-one peptide mimic synthe-
sis and conformational a analysis. Org Lett 14:4552–4555. doi:10.1021/
ol302021n
Scherer G, Kramer ML, Schutkowski M, Reimer U, Fischer G (1998) Barriers to 
rotation of secondary amide peptide bonds. J Am Chem Soc 120:5568–
5574. doi:10.1021/ja980181t
Vidal J, Hannachi J-C, Hourdin G, Mulatier J-C, Collet A (1998) N-Boc-
3-trichloromethyloxaziridine: a new, powerful reagent for elec-
trophilic amination. Tetrahedron Lett 39:8845–8848. doi:10.1016/
S0040-4039(98)01983-2
Vijayadas KN, Nair RV, Gawade RL, Kotmale AS, Prabhakaran P, Gonnade RG, 
Puranik VG, Rajamohanan PR, Sanjayan GJ (2013) Ester vs. amide on 
Page 12 of 12Suć and Jerić  SpringerPlus  (2015) 4:507 
folding: a case study with a 2-residue synthetic peptide. Org Biomol 
Chem 11:8348–8356. doi:10.1039/c3ob41967c
Wawra S, Fisher G (2006) Amide cis-trans isomerization in peptides and 
proteins. In: Dugave C (ed) Cis–trans isomerization in biochemistry. Wiley, 
KGaA, Weinheim, pp 167–193
Wu H, Qiao Q, Hu Y, Teng P, Gao W, Zuo X, Wojtas L, Larsen RW, Ma S, Cai J 
(2015) Sulfono-γ-AA peptides as a new class of nonnatural helical fol-
damer. Chem Eur J 21:2501–2507. doi:10.1002/chem.201406112
Zhu YY, Wang GT, Li ZT (2011) Molecular recognition with lin-
ear molecules as receptors. Curr Org Chem 15:1266–1292. 
doi:10.2174/138527211795378218
